KEGG   DRUG: Idecabtagene vicleucel
Entry
D11556                      Drug                                   

Name
Idecabtagene vicleucel (USAN);
Abecma (TN)
Product
Remark
Product: D11556<US>
Efficacy
Antineoplastic, Anti-BCMA CAR-T cell
  Disease
Multiple myeloma [DS:H00010]
Comment
Cellular therapy product
Target
TNFRSF17 (BCMA, CD269) [HSA:608] [KO:K05153]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04672  Intestinal immune network for IgA production
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Tumor necrosis factor receptors
    TNFRSF17 (BCMA, CD269)
     D11556  Idecabtagene vicleucel (USAN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D11556
New drug approvals in Europe [br08329.html]
 Cellular and gene therapy products
  D11556
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11556
Other DBs
PubChem: 384585532
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system